Philippe Laffont
INO icon

Philippe Laffont’s Inovio Pharmaceuticals INO Stock Holding History

Philippe Laffont’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-260,577
Closed -$29M – 79
2021
Q1 		$29M Sell
260,577
-37,500
-13% -$4.93M 0.16% 46
2020
Q4 		$31.7M Hold
298,077
– – 0.12% 60
2020
Q3 		$41.5M Buy
298,077
+68,910
+30% +$14.4M 0.22% 46
2020
Q2 		$74.1M Buy
+229,167
New +$36.8M 0.65% 31

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Philippe Laffont's INO Position: Q2 2021 in Review

Philippe Laffont sold out of Inovio Pharmaceuticals (INO) in Q2 2021, closing a stake of 260,577 shares — an estimated $29M sold.

Philippe Laffont first reported a position in INO in Q2 2020 and held it in 4 quarters. The position peaked at $74.1M in Q2 2020. 211 funds tracked by Wall St. Rank hold INO as of Q2 2021.

  • Philippe Laffont reported no remaining Inovio Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Philippe Laffont sold 260,577 Inovio Pharmaceuticals shares in Q2 2021, an estimated $29M.
  • Philippe Laffont first reported a position in Inovio Pharmaceuticals in Q2 2020 and held it in 4 quarters.
  • Philippe Laffont's Inovio Pharmaceuticals position peaked at $74.1M in Q2 2020.
  • 211 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2021.

Based on Coatue Management's 13F filing for Q2 2021, filed 13 Aug 2021.